Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

While death rates from cardiovascular disease have declined 60% since 1950, a recent upward trend aligns with increases in ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

Led by Moya Flaherty and Vicky O’Neil, Northampton General Hospitals NHS Trust Background to learning For many staff the COVID-19 pandemic represents the most extraordinary period of their careers. ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

The agency charged with insuring New Mexico state government reported a negative balance of $3.9 million in its settlement ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

Clinical guidelines for primary prevention of type 2 diabetes in Southeast Asia emphasize screening, diagnosis, and ...